Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulin Toxin for Localized Provoked Vulvodynia
NCT01747161Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Dec 2013
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in localized provoked vulvodynia (LPV) (2 arms), sponsored by Ghent University Hospital. Primary endpoints: Efficacy in alleviating dyspareunia (Provoked Pain) at 18 weeks and Safety and Adverse Events at 18 weeks. Started Dec 2013; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
localized provoked vulvodynia (LPV)
Beyond the preview
Go deeper on NCT01747161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01747161.